article thumbnail

The Massachusetts Avenue of health reform

The Health Policy Exchange

In contrast to the personality-driven path that Lyndon Johnson took to navigate legislative obstacles to Medicare and Medicaid, former management consultant Mitt Romney charted a decidedly different course to expanding health insurance when he became governor of Massachusetts in 2003. Together, Romney and Kennedy approached the George W.

Insurance 130
article thumbnail

FDA Adds Additional Q&As in the Final CMC Postapproval Changes Guidance

FDA Law Blog

This final guidance provides recommendations to original applicants and holders of approved applications for human drugs and certain biological products on implementing chemistry, manufacturing, and controls (CMC) postapproval changes(s) through the use of a Comparability Protocol (CP).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What to know about High Blood Pressure (Hypertension)

Georgetown Pediatrics & Family Medicine

The Joint National Committee 2003 defines hypertension as systolic of 140 mmHg and higher or diastolic 90 mmHg and higher. If you have any further questions or concerns, please talk with your primary care provider at your next appointment. What are some signs and symptoms of Hypertension?

article thumbnail

GeneSight® Mental Health Monitor Results

Myriad Genetics

It’s encouraging to see patients recognize what we, as healthcare providers, already know—that medications can be an effective option for people struggling with depression, anxiety, and other mental health conditions,” said Dr. Brown. He was elected to serve AAPOR as its Vice President, President, and Past President from 2011-2014.

article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

FDA Law Blog

Importantly though, the Policy Statement does not provide any insight into the types of listings that do not meet the statutory criteria and thus would be considered anticompetitive. And FDA did not provide a substantive response to 5 Requests for Advisory Opinions seeking clarification of the issue.

article thumbnail

Transition Plans for Covid-19 Products are Amongst CDRH FY2023 Priorities

FDA Law Blog

Also part of FDA’s FY2023 guidance document plan is a retrospective review of guidance documents issued in 1993, 2003, and 2013. FDA’s retrospective review of the 2003 guidance documents will include user labeling for devices that contain natural rubber and premarket approval application modular review.

Medical 52
article thumbnail

Navigating the Quademic: Clinical Differentiation of Influenza, RSV, COVID-19, and Norovirus in Pediatric Emergency Care

PEMBlog

This article delineates the salient clinical features, associated complications, cost considerations, and risk profiles for each virus, thereby providing a framework for informed clinical decision-making. MMWR Recomm Rep 2003; 52:1. Clin Microbiol Infect 2003; 9:247. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.Available

Clinic 52